A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + Pembrolizumab Dual Therapy With or Without Bevacizumab (BL-B01D1 + Pembrolizumab ± Bevacizumab) in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Latest Information Update: 22 Jul 2025
At a glance
- Drugs Izalontamab brengitecan (Primary) ; Bevacizumab; Pembrolizumab
- Indications Cervical cancer; Endometrial cancer
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 22 Jul 2025 New trial record